Treating pain in patients with hepatic impairment
US9421200B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 13, 2016 |
| Grant date | Aug 23, 2016 |
| Priority date | — |
| Expiry date | May 13, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5084
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.